<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Orforglipron: what changed | Grey Peptides</title>
    <link>https://greypeptides.com/changes/#e-orforglipron</link>
    <atom:link href="https://greypeptides.com/changes/orforglipron.xml" rel="self" type="application/rss+xml" />
    <description>News, regulatory alerts, corrections and new guides about Orforglipron on Grey Peptides, newest first.</description>
    <language>en-us</language>
    <lastBuildDate>Fri, 16 Oct 2026 12:00:00 +0000</lastBuildDate>
    <ttl>1440</ttl>
    <item>
      <title>News: Elecoglipron in Phase 2: What the VISTA and SOLSTICE Trials Show</title>
      <link>https://greypeptides.com/news/elecoglipron-phase-2-vista-solstice/</link>
      <guid isPermaLink="false">greypeptides-changes-orforglipron-news-elecoglipron-phase-2-vista-solstice</guid>
      <pubDate>Fri, 16 Oct 2026 12:00:00 +0000</pubDate>
      <category>News</category>
      <description>Elecoglipron in Phase 2: What the VISTA and SOLSTICE Trials Show</description>
    </item>
    <item>
      <title>Regulatory alert: US FDA: FDA published a major revision of Import Alert 66-80, which lets it detain GLP-1 bulk ingredients from foreign sites not on its Green List without examination, updating the Green List criteria and adding product codes, including one for orforglipron.</title>
      <link>https://greypeptides.com/regulatory/alerts/#fda-import-alert-66-80-revised</link>
      <guid isPermaLink="false">greypeptides-changes-orforglipron-alert-fda-import-alert-66-80-revised</guid>
      <pubDate>Fri, 09 Oct 2026 12:00:00 +0000</pubDate>
      <category>Regulatory alert</category>
      <description>The alert governs the raw ingredient that compounders import, not a finished product a patient buys. FDA says 21% of the 48 GLP-1 ingredient sites it reviewed were noncompliant, and that some sites registered, offered ingredients for import, refused records requests and deregistered.</description>
    </item>
    <item>
      <title>News: Ozempic Pill Reaches US Pharmacies: Oral Semaglutide for Type 2 Diabetes Under the Ozempic Name</title>
      <link>https://greypeptides.com/news/ozempic-oral-pill-us-launch-type2-diabetes/</link>
      <guid isPermaLink="false">greypeptides-changes-orforglipron-news-ozempic-oral-pill-us-launch-type2-diabetes</guid>
      <pubDate>Mon, 04 May 2026 12:00:00 +0000</pubDate>
      <category>News</category>
      <description>Ozempic Pill Reaches US Pharmacies: Oral Semaglutide for Type 2 Diabetes Under the Ozempic Name</description>
    </item>
    <item>
      <title>News: Foundayo (Orforglipron) Approved: A Small-Molecule GLP-1 Pill for Weight Loss</title>
      <link>https://greypeptides.com/news/foundayo-orforglipron-fda-approval/</link>
      <guid isPermaLink="false">greypeptides-changes-orforglipron-news-foundayo-orforglipron-fda-approval</guid>
      <pubDate>Thu, 02 Apr 2026 12:00:00 +0000</pubDate>
      <category>News</category>
      <description>Foundayo (Orforglipron) Approved: A Small-Molecule GLP-1 Pill for Weight Loss</description>
    </item>
  </channel>
</rss>
